Bolt Biotherapeutics Inc
NASDAQ:BOLT
| Market Cap (Intraday) | 9.53M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.25 |
| 50-Day MA | $5.69 |
| 200-Day MA | $8.14 |
Bolt Biotherapeutics Inc Stock, NASDAQ:BOLT
900 Chesapeake Drive, Redwood City, California 94063
United States of America
Phone: +1.650.665.9295
Number of Employees: 100
Description
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.